N-Acetylneuraminic acid is a nine-carbon, sialic acid monosaccharide commonly found in glycoproteins on cell membranes and in glycolipids such as gangliosides in mammalian cells.Synthesis of pyrrolidine analogues of N‐acetylneuraminic acid could as potential sialidase inhibitors. N-Acetylneuraminic acid-containing substances has growth-promoting effects on bifidobacteria, a number of N-acetylneuraminic acid-based compounds as potential rotavirus inhibitors. N-acetyl-beta-neuraminic acid is N-Acetylneuraminic acid with beta configuration at the anomeric centre. It has a role as an epitope. It is functionally related to a beta-neuraminic acid. It is a conjugate acid of a N-acetyl-beta-neuraminate.

Fraxin is a beta-D-glucoside that is fraxetin attached to a beta-D-glucopyranosyl group at position 8 via a glycosidic linkage. It is a natural product isolated from the leaves of Fraxinus excelsior and exhibits potent hepatoprotective effects in vitro and in vivo. It has a role as a hepatoprotective agent, an anti-inflammatory agent and a plant metabolite. It is a beta-D-glucoside, an aromatic ether and a hydroxycoumarin. It is functionally related to a fraxetin. Fraxin possesses a variety of bioactivities such as anti-inflammatory, antioxidant, analgesic, antimicrobial, antiviral, immunomodulatory, anti-hyperuricemia and diuresis. Fraxin enhances urate excretion partly by inhibiting mURAT1 or mGLUT9 in kidney of hyperuricemic mice.

1. Kaempferol activates LXR-β and suppresses SREBP-1 to enhance symptoms in metabolic syndrome. 2. Kaempferol exerts a potent inhibitory effect on in vitro bone resorption. 3. Kaempferol has anti-inflammatory action, can prevent and treat inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis. 4. Kaempferol has therapeutic potential for the prevention and treatment of thrombovascular diseases, can enhance relaxations caused by endothelium-derived and exogenous NO as well as those due to endothelium-dependent hyperpolarization. 5. Kaempferol can inhibit cancer cell invasion through blocking the PKCδ/MAPK/AP-1 cascade and subsequent MMP-9 expression and its activity, may act as a therapeutic potential candidate for cancer metastasis. 6. Kaempferol is an autophagic enhancer, has a more general protection in Parkinson's disease, can mediate antiapoptotic and antioxidant effects is the enhancement of mitochondrial turnover by autophagy.

1. Kaempferol activates LXR-β and suppresses SREBP-1 to enhance symptoms in metabolic syndrome. 2. Kaempferol exerts a potent inhibitory effect on in vitro bone resorption. 3. Kaempferol has anti-inflammatory action, can prevent and treat inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis. 4. Kaempferol has therapeutic potential for the prevention and treatment of thrombovascular diseases, can enhance relaxations caused by endothelium-derived and exogenous NO as well as those due to endothelium-dependent hyperpolarization. 5. Kaempferol can inhibit cancer cell invasion through blocking the PKCδ/MAPK/AP-1 cascade and subsequent MMP-9 expression and its activity, may act as a therapeutic potential candidate for cancer metastasis. 6. Kaempferol is an autophagic enhancer, has a more general protection in Parkinson's disease, can mediate antiapoptotic and antioxidant effects is the enhancement of mitochondrial turnover by autophagy.